Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.
The diagnosis of LTBI is primarily based on the results of the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), also known as the QuantiFERON-TB Gold In-Tube (GFT-GIT) test.
The test for adrenal antibodies was negative ... negative adrenal antibodies, normal ESR and negative QuantiFERON-TB Gold Plus. The patient’s treatment plan included long-term oral hydrocortisone 20 ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection. "Protecting our intellectual property is essential to ensuring continued innovation in infectious ...
Tracking targeted drug delivery is often a challenge due to limitations in current imaging techniques. A recent study by ...
Tracking targeted drug delivery is often a challenge due to limitations in the current imaging techniques. A recent study reports a breakthrough imaging technique that allows direct and highly ...
Join American Rifleman staff on the range in this episode to learn about Mossberg’s International Gold Reserve model, the company's self-proclaimed “top-shelf” shotgun featuring an aluminum 20-ga.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback